Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science, emphasized the strategic importance of this move, stating, "The Asia-Pacific region serves as a vibrant hub for cutting-edge research and development in biotechnology, mRNA, and gene therapy. By enhancing our presence here, we aim to forge stronger partnerships with our customers and accelerate the delivery of novel therapies to patients."

The new Bioprocessing Production Center is poised to cater to the evolving needs of biotechnology and pharmaceutical firms engaged in the development, clinical research, and commercial production of biologics. These complex biological compounds include vaccines, cell and gene therapies, and protein-based treatments like monoclonal antibodies – all vital components of modern healthcare.

Spanning an impressive 43,000 square meters, the facility will boast advanced production capabilities alongside a distribution center and automated warehouse. It will provide essential biotech products such as dry powder cell culture media, process liquids, pre-GMP small-scale manufacturing, and sterile sampling systems.

This investment underscores Merck's commitment to advancing public health and supporting the global fight against diseases. The company's footprint in South Korea dates back to 1989, and the addition of this cutting-edge facility further solidifies its position as a key player in driving scientific innovation in the region.

With an anticipated creation of approximately 300 jobs by 2028, Merck's investment not only bolsters its operational capabilities but also contributes to the local economy. This initiative aligns with Merck's broader multi-year investment program aimed at enhancing industrial capacity and capabilities in the Life Science sector globally.

Merck's unwavering dedication to fostering collaboration and innovation underscores its mission to transform healthcare and improve lives worldwide. This milestone investment in South Korea represents a significant step forward in achieving this vision